Virpax Pharmaceuticals, Inc. Contracts & Agreements

Extension Agreement, dated September 30, 2024, between Virpax Pharmaceuticals, Inc. and Corbo Capital Inc (Filed With SEC on October 3, 2024)

Form of Placement Agency Agreement (Filed With SEC on August 13, 2024)

Form of Pre-Funded Warrant for this Offering (Filed With SEC on August 13, 2024)

Form of Securities Purchase Agreement to be entered into in this Offering (Filed With SEC on August 13, 2024)

Amendment to the Virpax Pharmaceuticals, Inc. 2022 Equity Incentive Plan to Increase in Authorized Shares (Filed With SEC on July 30, 2024)

Amendment to the Virpax Pharmaceuticals, Inc. 2022 Equity Incentive Plan to Increase Evergreen Provision Percentage (Filed With SEC on July 30, 2024)

Form of Secured Note (Filed With SEC on July 8, 2024)

Securities Purchase Agreement, dated July 5, 2024, by and between Virpax Pharmaceuticals, Inc. and Corbo Capital Inc (Filed With SEC on July 8, 2024)

Security Agreement, dated July 5, 2024, by and between Virpax Pharmaceuticals, Inc. and Corbo Capital Inc (Filed With SEC on July 8, 2024)

Placement Agency Agreement, dated as of May 14, 2024, by and between Virpax Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners, as placement agent (Filed With SEC on May 17, 2024)

Form of Series A-1 Common Warrant (Filed With SEC on May 17, 2024)

Form of Series A-2 Common Warrant (Filed With SEC on May 17, 2024)

Form of Pre-Funded Warrant (Filed With SEC on May 17, 2024)

Form of Securities Purchase Agreement (Filed With SEC on May 17, 2024)

PlacementAgency Agreement (Filed With SEC on May 13, 2024)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on May 13, 2024)

Separation Agreement between Virpax Pharmaceuticals, Inc. and Jeffrey Gudin, MD, dated May 2, 2024 (Filed With SEC on May 2, 2024)

Form of Series A-1 Common Warrant (Filed With SEC on May 2, 2024)

Form of Series A-2 Common Warrant (Filed With SEC on May 2, 2024)

Form of Pre-Funded Warrant (Filed With SEC on May 2, 2024)

Form of Securities Purchase Agreement to be entered into in this Offering (Filed With SEC on May 2, 2024)

Form of Placement Agency Agreement (Filed With SEC on April 18, 2024)

Form of Common Warrant (Filed With SEC on April 18, 2024)

Form of Pre-Funded Warrant (Filed With SEC on April 18, 2024)

Form of Securities Purchase Agreement to be entered into in this Offering (Filed With SEC on April 18, 2024)

Description of Securities (Filed With SEC on March 26, 2024)

Employment Agreement, dated April 7, 2021, by and between Virpax Pharmaceuticals, Inc. and Sheila Mathias (Filed With SEC on March 26, 2024)

Indemnification Agreement, dated March 25, 2024, by and between Virpax Pharmaceuticals, Inc. and Vinay Shah (Filed With SEC on March 26, 2024)

Settlement Agreement and Mutual Release between Virpax Pharmaceuticals, Inc. and Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc (Filed With SEC on March 1, 2024)

Employment Agreement, dated December 6, 2023, by and between Virpax Pharmaceuticals, Inc. and Gerald Bruce (Filed With SEC on December 7, 2023)

Amendment to Employment Agreement, dated August 15, 2023, by and between Virpax Pharmaceuticals, Inc. and Anthony Mack (Filed With SEC on August 16, 2023)

Employment Agreement, dated June 20, 2023, by and between Virpax Pharmaceuticals, Inc. and Vinay Shah (Filed With SEC on June 21, 2023)

Separation agreement, dated June 18, 2023 by and between Virpax Pharmaceuticals, Inc. and Christopher Chipman (Filed With SEC on June 21, 2023)

DESCRIPTION OF THE REGISTRANT’S SECURITIESREGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGEACT OF 1934 (Filed With SEC on March 22, 2023)

Virpax Pharmaceuticals, Inc. 2022 Omnibus Equity Incentive Plan (Filed With SEC on July 25, 2022)

Virpax Pharmaceuticals, Inc. Form of Nonqualified Stock Option Grant Agreement (Filed With SEC on July 25, 2022)

Virpax Pharmaceuticals, Inc. Form of Incentive Stock Option Grant Agreement (Filed With SEC on July 25, 2022)

Virpax Pharmaceuticals, Inc. Form of Restricted Stock Award Agreement (Filed With SEC on July 25, 2022)

Virpax Pharmaceuticals, Inc. Form of Restricted Stock Unit Award Agreement (Filed With SEC on July 25, 2022)

Description of Securities (Filed With SEC on March 31, 2022)

Amendment No. 1, dated March 29, 2022, to the Employment Agreement by and between Virpax Pharmaceuticals, Inc. and Anthony Mack, dated September 18, 2017 (Filed With SEC on March 31, 2022)

Amendment No. 1, dated March 29, 2022, to the Employment Agreement by and between Virpax Pharmaceuticals, Inc. and Christopher M. Chipman, dated April 7, 2021 (Filed With SEC on March 31, 2022)

Amendment No. 1, dated March 29, 2022, to the Employment Agreement by and between Virpax Pharmaceuticals, Inc. and Jeffrey Gudin, MD, dated April 15, 2021 (Filed With SEC on March 31, 2022)

Amended and Restated Collaboration and License Agreement between Nanomerics Ltd. and Virpax Pharmaceuticals, Inc., dated as of March 9, 2022 (Filed With SEC on March 31, 2022)

Form of Underwriting Agreement (Filed With SEC on September 9, 2021)

Agreement for Rendering of Research Services between LipoCureRx, Ltd. and Virpax Pharmaceuticals, Inc., dated June 29, 2021 (Filed With SEC on September 9, 2021)

Agreement for Rendering of Research Services between Virpax Pharmaceuticals, Inc. and Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd., dated June... (Filed With SEC on September 9, 2021)

Amendment to the Collaboration and License Agreement dated April 11, 2019, as amended, between Nanomerics Ltd. and Virpax Pharmaceuticals, Inc., dated April 6, 2021 (Filed With SEC on August 10, 2021)

Amendment to the Collaboration and License Agreement dated April 11, 2019, as amended, between Nanomerics Ltd. and Virpax Pharmaceuticals Inc., dated May 5, 2021 (Filed With SEC on August 10, 2021)

First Amendment to the Amended and restated Virpax Pharmaceuticals, Inc. 2017 Equity Incentive Plan, dated April 25, 2020 (Filed With SEC on August 10, 2021)

Gudin Employment Agreement (Filed With SEC on April 19, 2021)

Chipman Employment Agreement (Filed With SEC on April 13, 2021)

Description of Securities (Filed With SEC on March 31, 2021)

Form of Underwriting Agreement (Filed With SEC on February 2, 2021)

Form of Underwriters Warrant (Filed With SEC on February 2, 2021)

Amendment No. 1 to the Collaboration and License Agreement between Nanomerics Ltd. and Virpax Pharmaceuticals, Inc., dated as of December 31, 2020 (Filed With SEC on January 8, 2021)

Fourth Amendment to the Services Convertible Promissory Note, dated as of December 31, 2020, between Virpax Pharmaceuticals, Inc. and RRD International, LLC (Filed With SEC on January 8, 2021)

Short Term Note Agreement between Anthony P. Mack and Virpax Pharmaceuticals, Inc., dated January7, 2021 (Filed With SEC on January 8, 2021)

Short Term Note Agreement between Christopher Chipman and Virpax Pharmaceuticals, Inc., dated January 7, 2021 (Filed With SEC on January 8, 2021)

Service Provider Convertible Note Purchase Agreement, dated August 29, 2019, between Virpax Pharmaceuticals, Inc. and RRD International, LLC (Filed With SEC on December 16, 2020)

Third Amendment to the Services Convertible Promissory Note, dated as of November 30, 2020, between Virpax Pharmaceuticals, Inc. and RRD International, LLC (Filed With SEC on December 16, 2020)

Form of Indemnification Agreement entered into by Virpax Pharmaceuticals, Inc. with its Officers and Directors (Filed With SEC on November 20, 2020)

License Agreement by and between MedPharm Limited and Virpax Pharmaceuticals, Inc., dated as of June 6, 2017 (Filed With SEC on November 20, 2020)

First Amendment to the License Agreement by and between MedPharm Limited and Virpax Pharmaceuticals, Inc., dated as of September 2, 2017 (Filed With SEC on November 20, 2020)

Second Amendment to the License Agreement by and between MedPharm Limited and Virpax Pharmaceuticals, Inc., dated as of October 31, 2017 (Filed With SEC on November 20, 2020)

Research and Option Agreement by and between MedPharm Limited and Virpax Pharmaceuticals, Inc., dated as of April 11, 2017 (Filed With SEC on November 20, 2020)

First Amendment to the Research and Option Agreement by and between MedPharm Limited and Virpax Pharmaceuticals, Inc., dated as of May 30, 2018 (Filed With SEC on November 20, 2020)

License and Sublicense Agreement by and between LipoCureRx, Ltd. and Virpax Pharmaceuticals, Inc., dated as of March 19, 2018 (Filed With SEC on November 20, 2020)

Collaboration and License Agreement by and between Nanomerics Ltd. and Virpax Pharmaceuticals, Inc., dated as of April 11, 2019 (Filed With SEC on November 20, 2020)

Amendment to the Collaboration and License Agreement by and between Nanomerics Ltd. and Virpax Pharmaceuticals, Inc., dated as of December 30, 2019 (Filed With SEC on November 20, 2020)

Research and License Agreement by and between Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. and Virpax Pharmaceuticals, Inc., dated as of August... (Filed With SEC on November 20, 2020)

First Amendment to the Research and License Agreement by and between Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. and Virpax Pharmaceuticals,... (Filed With SEC on November 20, 2020)

Agreement for the Rendering of Research Services by and between Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. and Virpax Pharmaceuticals, Inc.,... (Filed With SEC on November 20, 2020)

Collaboration and License Agreement between Nanomerics Ltd. and Virpax Pharmaceuticals, Inc., dated August 7, 2020 (Filed With SEC on November 20, 2020)

Amendment No. 2 to the Promissory Note Dated October 1, 2018, dated October 28, 2020, between Anthony Mack and Virpax Pharmaceuticals, Inc (Filed With SEC on November 20, 2020)

Amendment No. 2 to the Promissory Note Dated January 15, 2019, dated October 28, 2020, between Anthony Mack and Virpax Pharmaceuticals, Inc (Filed With SEC on November 20, 2020)

Specimen Certificate representing shares of common stock of Virpax Pharmaceuticals, Inc (Filed With SEC on October 9, 2020)

Form of Consultant Warrant (Filed With SEC on October 9, 2020)

Virpax Pharmaceuticals, Inc. 2017 Equity Incentive Plan (Filed With SEC on October 9, 2020)

Form of Nonqualified Stock Option Award under 2017 Equity Incentive Plan (Filed With SEC on October 9, 2020)

Form of Incentive Stock Option Award under 2017 Equity Incentive Plan (Filed With SEC on October 9, 2020)

Employment Agreement by and between Virpax Pharmaceuticals, Inc. and Anthony Mack, dated as of September 18, 2018 (Filed With SEC on October 9, 2020)

Consulting Agreement by and between Virpax Pharmaceuticals, Inc. and Gerald Bruce, dated as of March 11, 2020 (Filed With SEC on October 9, 2020)

Promissory Note, dated October 1, 2018, between Anthony Mack and Virpax Pharmaceuticals, Inc (Filed With SEC on October 9, 2020)

Amendment No. 1 to the Promissory Note Dated October 1, 2018, dated April 6, 2020, between Anthony Mack and Virpax Pharmaceuticals, Inc (Filed With SEC on October 9, 2020)

Promissory Note, dated January 15, 2019, between Anthony Mack and Virpax Pharmaceuticals, Inc (Filed With SEC on October 9, 2020)

Amendment No. 1 to the Promissory Note Dated January 15, 2019, dated April 6, 2020, between Anthony Mack and Virpax Pharmaceuticals, Inc (Filed With SEC on October 9, 2020)

Service Provider Convertible Note Purchase Agreement, dated August 29, 2019, between Virpax Pharmaceuticals, Inc. and RRD International, LLC (Filed With SEC on October 9, 2020)

First Amendment to the Services Convertible Promissory Note, dated March 25, 2020, between Virpax Pharmaceuticals, Inc. and RRD International, LLC (Filed With SEC on October 9, 2020)

Second Amendment to the Services Convertible Promissory Note, dated as of September 30, 2020, between Virpax Pharmaceuticals, Inc. and RRD International, LLC (Filed With SEC on October 9, 2020)

Paycheck Protection Program Term Note, dated May 4, 2020, between Virpax Pharmaceuticals, Inc. and PNC Bank, National Association (Filed With SEC on October 9, 2020)

Cooperative Research and Development Agreement, dated August 25, 2020, between the U.S. Department of Health and Human Services, as represented by National Center for Advancing... (Filed With SEC on October 9, 2020)

Independent Contractor Agreement, dated May 1, 2020, between Virpax Pharmaceuticals, Inc. and Chipman & Chipman, LLC (Filed With SEC on October 9, 2020)

Category

Industry

Companies

Contracts

Virpax Pharmaceuticals, Inc. Contracts & Agreements